Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658406 | 0.87 | MCHR1 (0.46) | SYKMCHR1NPY5RHRH3SMN1; SMN2 | |
| SCHEMBL7287775 | 0.84 | GFER (0.54) | SYKMCHR1NPY5RHRH3MAP4K4 | |
| SCHEMBL19658493 | 0.82 | MCHR1 (0.49) | SYKMCHR1NPY5RHRH3SMN1; SMN2 | |
| SCHEMBL3440206 | 0.82 | RORC (0.47) | MCHR1LSSRORC | |
| SCHEMBL14167600 | 0.81 | NPY5R (0.58) | SYKMCHR1NPY5RHRH3MAP4K4 | |
| SCHEMBL19658738 | 0.81 | NPY5R (0.56) | SYKMCHR1NPY5RUSP2NPC1 | |
| SCHEMBL19658390 | 0.79 | NOTUM (0.55) | SYKMCHR1NPY5RSMN1; SMN2 | |
| SCHEMBL19658405 | 0.79 | PANK3 (0.47) | SYKMCHR1NPY5RHRH3SMN1; SMN2 | |
| SCHEMBL22928897 | 0.78 | SYK (0.49) | SYKMCHR1NPY5RHRH3MAP4K4 | |
| SCHEMBL22919403 | 0.78 | NPY5R (0.46) | SYKMCHR1NPY5RHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024495-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| WO-2021013830-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024495-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | SYK 3116/4885MCHR1 2832/4885NPY5R 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.